LEU — Centrus Energy Corp.
$170.00
Target: $264.73 (+55.7%)
P/E Ratio
61.8
P/E Forward
43.1
Dividend
—
Market Cap
$3.36B
EPS
$2.75
Consensus
Buy
What they do
Centrus Energy Corp. (NYSE American: LEU) is a US nuclear fuel company. Its core business is uranium enrichment: taking natural uranium and raising the concentration of the U-235 isotope to the level a reactor needs to generate electricity. Headquartered in Bethesda, Maryland; production plant in Piketon, Ohio.
Two segments:
**
- LEU (Low-Enriched Uranium)** — sells standard nuclear fuel to electric utilities that operate nuclear plants in the US and worldwide. Historically bought some material from third parties (including Russia) and resold it; now rebuilding its own domestic enrichment capacity.
**
- HALEU (High-Assay Low-Enriched Uranium) — the strategic crown jewel. Uranium enriched to higher purity (up to ~20%), the fuel required by small modular reactors (SMRs) and next-generation advanced reactors. Centrus is the only NRC-licensed facility** to produce HALEU in the US, at its Piketon, Ohio plant.
Why this matters: after the invasion of Ukraine, the US banned imports of Russian enriched uranium (Russia controlled ~40–50% of the global enrichment market). That left a massive gap in the Western nuclear supply chain. Centrus is the US government's bet on restoring domestic production: it received a Department of Energy (DOE) order worth ~$900M and holds a pipeline of signed orders worth ~$3.9 billion through 2040.
Leadership: CEO Amir Vexler. The company does NOT pay a dividend — it reinvests everything in expanding enrichment capacity. Q1 2026: revenue $76.7M, EPS $0.45. The stock is highly volatile: it fell from ~$189 to ~$165 after a Q1 that came in below expectations.
Why we like it
Buying LEU at $170.00 means REINFORCING (we'd already held it since June 8 at $167.07) the ONLY American-owned producer able to enrich uranium in the U.S., right when the country is legally required to stop depending on Russia for its nuclear fuel — and now with the government's $900M contract firmly signed. Specific reasons:
- Strategic HALEU monopoly: Centrus is the only facility licensed to produce the fuel (HALEU) that next-generation nuclear reactors need. Without that fuel, the entire SMR industry can't get going —and Centrus is the bottleneck—.
- Geopolitical tailwind: the U.S. banned Russian enriched uranium; Russia controlled ~40-50% of the global market. Rebuilding Western capacity is now a national-security priority, with federal money behind it.
- Government backing: a DOE order of ~$900M + a backlog of ~$3.9 billion in orders through 2040 —very long-term revenue visibility—.
- Nuclear renaissance: electricity demand from AI data centers is pushing the tech giants (Microsoft, Amazon, Google) to sign nuclear deals; more reactors = more demand for enriched fuel.
- Capacity catalyst: every new centrifuge cascade Centrus brings online in Piketon multiplies its production capacity. Analysts: 'Moderate Buy', average target ~$268 (~+60%).
Key Risk
Risks:
- Very high valuation — #1: at ~58x earnings, the price already bakes in a lot of optimism. If capacity expansion is delayed or HALEU orders arrive more slowly, the stock can correct sharply (as it already did: -13% after a weak quarter).
- No dividend: it is 100% a growth bet; you receive no income while you wait.
- Government dependency: a large part of the investment case depends on DOE funding and contracts; a change in political priorities or federal budget hits directly.
- Technical execution: enriching uranium is among the most complex and regulated processes in existence; any operational, licensing (NRC) or safety issue can halt production.
- Extreme volatility: it is a 'theme stock' that moves with nuclear energy headlines, not stable fundamentals — not for the faint of heart.
- SMR demand still early: next-generation reactors are still being built; if their deployment is delayed by years, HALEU demand takes longer to materialize.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked LEU on 2026-06-08 at $170.00.
Full Research
Centrus Energy (LEU) — Research Completo
Precio: $167.07 | P/E TTM: ~58.6x | Div Yield: 0% | Market Cap: ~$3.25B USD
¿Qué es Centrus?
La única empresa de capital estadounidense que enriquece uranio —el combustible nuclear— en suelo de EE.UU. HQ Bethesda, Maryland; planta en Piketon, Ohio. NO paga dividendo: reinvierte todo en capacidad.
2 Segmentos
| Segmento | Qué es | Nota |
|---|---|---|
| LEU (bajo enriquecimiento) | Combustible nuclear estándar para plantas | Reconstruyendo producción doméstica |
| HALEU (alto enriquecimiento) | Combustible para reactores de nueva generación (SMRs) | ÚNICA planta con licencia NRC en EE.UU. |
El caso geopolítico
- Tras invadir Ucrania, EE.UU. prohibió importar uranio enriquecido ruso.
- Rusia controlaba ~40-50% del mercado mundial de enriquecimiento.
- Centrus = la apuesta de EE.UU. para recuperar producción doméstica.
- Orden del DOE: ~$900M | Backlog: ~$3.9 mil millones hasta 2040.
Q1 2026
| Métrica | Q1 2026 |
|---|---|
| Ingresos | $76.7M |
| EPS | $0.45 |
| Reacción | -13% (cayó de ~$189 a ~$165, trimestre bajo expectativas) |
Liderazgo
- CEO: Amir Vexler.
- Dividendo: $0 (100% reinversión).
Anchor Fact
Hay UNA sola empresa con permiso del gobierno de EE.UU. para fabricar el combustible que necesitan los reactores nucleares del futuro —y es Centrus—. Durante décadas, este combustible venía sobre todo de Rusia. Cuando EE.UU. prohibió comprarle a Rusia tras la guerra, quedó un hueco gigante: alguien tenía que producirlo en casa. Centrus es esa empresa, y el propio Departamento de Energía le firmó un pedido de ~$900 millones para que lo haga.
Top 5 Risks
- Valuación altísima (~58x) — el precio ya descuenta mucho optimismo
- NO paga dividendo — 100% apuesta por crecimiento
- Dependencia del gobierno — el caso depende de fondos del DOE
- Ejecución técnica + regulatoria (NRC) — enriquecer uranio es complejísimo
- Demanda de SMRs aún incipiente — los reactores nuevos tardan en desplegarse
Analyst Consensus
- Rating: Moderate Buy
- Target promedio: ~$268 (~+60% desde $167.07)
Tesis en una línea
El único productor estadounidense de combustible nuclear enriquecido, insustituible para la independencia energética de EE.UU. justo cuando el país tiene prohibido comprarle a Rusia.
Research fecha: 08 Jun 2026 | Próxima revisión: Dic 2026
Esto no es asesoría financiera.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.